SLC19A3 and biotin-responsive basal ganglia disease: CRISPR/Cas9-mediated knock-in of SLC19A3, coupled with in vitro disease modeling using midbrain organoids and gene expression profiling could be utilized to further our understanding of BTBGD pathogenesis, thus allowing for the discovery of more efficient therapeutic agents through drug screening.